Furthermore, decreased C-reactive protein levels were associated with both reductions in troponin T levels and greater 6-min walking distance
Severe GI adverse reactions were reported in 4.1% and 0.9% of Wegovy -injection treated and placebo treated patients, respectively, and in 2% of Wegovy tablet-treated and 0% of placebo treated patients, respectively
GLP-1 RAs Hold Promising Potential for Reduction of Cardiometabolic Risk Factors additional benefits : Brain: Appetite suppression, nerve protection, and decreased neuroinflammation Heart: Decreased blood pressure (systolic and diastolic), reduced total cholesterol levels, lowered endothelial dysfunction, and increased heart rate Liver: Decreased glucose production Pancreas: Increased insulin secretion, decreased glucagon secretion, B islet cell proliferation GI Tract: Decreased gastric emptying Because these drugs cause weight loss, it is not clear whether the GLP-1 RAs or the weight loss reduces cardiometabolic risks
This combination of actions makes Tirzepatide especially effective for people who have had difficulty losing weight with traditional methods like diet and exercise
A.ZemskyJ.PinnerE.KarpelR.PadanE.et al (1993)
